article thumbnail

DEA removes cannabis drug Epidiolex from controlled substances list

SMPL

Food and Drug Administration, is no longer considered a controlled substance, providing a boost to its manufacturer’s stock price. Epidiolex is used to treat rare forms of epilepsy. The DEA’s announcement lowers physician barriers to prescribing Epidiolex because they won’t have to notify the agency when prescribing it.

DEA 40
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA. will top $1.9

DEA 51
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Constitutionality of Cannabis: Federal Lawsuit Against DEA, DOJ Proceeds

Marijuana Lawyer Blog

Plaintiffs in the lawsuit include a 12-year-old epilepsy patient, an 8-year-old Leigh’s syndrome patient, an Iraq war veteran and sufferer of post-traumatic stress disorder, a former NFL player who heads a hemp company hawking sports performance products and a non-profit that helps minorities get ahead in the legal cannabis market.

DEA 40
article thumbnail

CBD Lawsuit Reflects Trucker Termination for THC Tainted Drug Products

The Blunt Truth

We have noted previously that the federal Drug Enforcement Agency (DEA) recently announced that drugs that include CBD (cannabidiol) with less than 0.1% of THC (tetrahydrocannabinols) are now considered Schedule V drugs provided they are approved by the federal Food and Drug Administration (FDA).

THC 87
article thumbnail

FDA Balks at CBD Dietary Supplement Application, Maintaining Regulatory Uncertainty

SpeedWeed

Food and Drug Administration (FDA) this week pushed back on applications for CBD to be sold as an ingestible dietary ingredient, sending a strong signal that the federal agency is not ready to budge on this ongoing regulatory issue. “CBD is the active ingredient in the approved drug product, Epidiolex.

CBD 52
article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

Drug Enforcement Agency (DEA). According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Groff confirmed that it had completed its first batch of medicinal-grade cannabis for research purposes on Feb.

article thumbnail

The Path to Greenlighting CBD

Burns Levinson (Cannabusiness advisory)

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. Under the CSA, CBD remains a Schedule I substance, which means that it is not considered to have any currently accepted medical use.

CBD 40